Federal Multidistrict Litigation Overview (MDL 3094) The federal judicial panel consolidated all Ozempic-related lawsuits into MDL 3094 in the Eastern District of Pennsylvania in February 2024, recognizing the common factual questions surrounding whether manufacturers knew or should have known about serious gastrointestinal risks
In a recent post-hoc analysis of SUSTAIN 6, semaglutide was associated with less events of nephropathy, independent of baseline blood pressure (119)
decreased urination or swelling, which could indicate kidney problems
Without adequate stomach acid, b12 remains bound to food proteins and passes through the digestive system unabsorbed
Doctor-supervised
Although PYY1875 demonstrated potential in preclinical studies and showed modest efficacy in clinical studies, the authors say, its tolerability issues, particularly [GI]-related AEs, limit its clinical utility as an add-on therapy to semaglutide for weight management in obesity. The authors highlight the difficulty of translating animal success to humans and suggest that future research may find that alternative dosing schedules, more tolerable formulations, or different combination regimens yield more impressive results